title: [What's new in dermatological research?].
abstract: Dermatology research has been very rich this year, once again. The physiopathological mechanisms of paradoxical reactions to anti-TNF are better understood and new therapeutic targets for psoriasis have been evidenced. Targeted therapy in oncodermatology have shown their potential usefulness clinically but fundamental data have also clarified their mechanisms of action as well as their limits. The key role played by the immune system in nonsegmental vitiligo has also been clearly demonstrated. Fibroblasts as well as visible light seem to play a key role that has been poorly understood to date within the complex mechanisms of cutaneous pigmentation. Specific receptors of pruritus have been reported and foster hope for the development of more effective antipruriginous treatments in the near future. Other studies report new potential targets for diseases such as fungoid mycosis, atopic dermatitis, or scleroderma. Finally, physiopathological explanations have contributed to a variety of domains such as greying hair, axillary odors, HIV and herpes virus interrelations, and the teratogenicity of thalidomide.
authors.affiliation: Service de Dermatologie & INSERM U895 équipe 1, CHU de Nice, route de St Antoine de Ginestière, 06200 Nice, France. passeron@unice.fr
authors.forename: Th
authors.initials: T
authors.lastname: Passeron
mesh_terms: D035843:Biomedical Research / Q000639:trends*; D003876:Dermatitis, Atopic / Q000628:therapy; D003880:Dermatology / Q000639:trends*; D015658:HIV Infections / Q000628:therapy / Q000821:virology; D006566:Herpesviridae Infections / Q000628:therapy / Q000821:virology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D009181:Mycoses / Q000628:therapy; D011565:Psoriasis / Q000628:therapy; D045743:Scleroderma, Diffuse / Q000628:therapy; D045745:Scleroderma, Limited / Q000628:therapy; D012871:Skin Diseases / Q000209:etiology / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy; D013792:Thalidomide / Q000009:adverse effects; D014820:Vitiligo / Q000628:therapy
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide